Supplementary Figure S5 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

Samantha I. Liang; Zoe Quandt; Sara Wienke; Jing Wang; Sean Gordon; Reagan M. Barnett; Jude Masannat; Kyle Chang; Carin R. Espenschied; Katie Quinn; Kimberly C. Banks; Enjun Yang; John E. Connolly

doi:10.1158/2767-9764.29948084

August 20, 2025Open Access

Supplementary Figure S5 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

View Full Paper

Ask AI

Bookmark

Share

Key Points

Low ctDNA tumor fraction indicates potential for long-term clinical benefit during treatment with immune checkpoint inhibitors.
Patients with tumor fraction values below limit of quantification (LOQ) at both timepoints exhibited better outcomes.
The study employed a real-world cohort, providing insights into the effectiveness of immune therapies across diverse cancer types.
This analysis emphasizes the importance of tumor fraction monitoring in clinical settings, guiding personalized treatment options.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Implication

Real-world analysis reveals that low tumor fraction correlates with outcomes in patients treated with immune checkpoint inhibitors across various cancers.

Abstract

Real-world outcomes of patients with TF below LOQ at both timepoints

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Liang et al. (2025) studied this question.

synapsesocial.com/papers/68af55d8ad7bf08b1eadc778 https://doi.org/10.1158/2767-9764.29948084

View Full Paper

Ask AI

Bookmark

Share

Supplementary Figure S5 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Supplementary Figure S5 from Methylation-Based ctDNA Tumor Fraction Changes Predict Long-Term Clinical Benefit From Immune Checkpoint Inhibitors in RADIOHEAD, a Real-World Pan-Cancer Study

Key Points

No abstract yet

Implication

Abstract

Discussion

Cite This Study

Keep reading

More related papers

Keep reading

More related papers